MP55-20 OUTCOMES OF PRIMARY CRYOTHERAPY FOR LOCALIZED PROSTATE CANCER: 14-YEARS SINGLE INSTITUTION EXPERIENCE

Abstract

You have accessJournal of UrologyCME1 May 2022MP55-20 OUTCOMES OF PRIMARY CRYOTHERAPY FOR LOCALIZED PROSTATE CANCER: 14-YEARS SINGLE INSTITUTION EXPERIENCE Andrew Wang, Greg Mansour, and Robert Given Andrew WangAndrew Wang More articles by this author , Greg MansourGreg Mansour More articles by this author , and Robert GivenRobert Given More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000002634.20AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Cryoablation, a minimally invasive ablative therapy, is recommended as an alternative treatment for localized prostate cancer (PCa) given its favorable side effect profiles on bladder and bowel function, especially in those with low- and intermediate-risk disease who are not suitable for surgery or radiation therapy. Long-term outcomes are not well characterized in the literature. We aim to report our experience with the procedure at our institution. METHODS: We retrospectively reviewed all men who underwent primary whole-gland cryoablation for localized prostate cancer at our institution from 2005 through 2019. Functional and oncologic outcomes were assessed. Recurrence-free survival was studied using Kaplan-Meier survival analysis. RESULTS: Of the 276 patients, 80% had D’Amico high- (22.8%) or intermediate- (57.6%) risk disease. Average age was 71.2 years while median follow-up was 4.7 years. Majority of the patients (83%) achieved prostate-specific antigen (PSA) nadir <0.4 ng/ml. This was associated with improved disease-free survival (p <0.00001). De novo incontinence (2%) and De novo ED rates (12%) were relatively low, and complications such as urethral stricture (n=1) and rectal urethral fistula (n=0) were extremely rare. 5 year clinical recurrence-free survival was 70% overall and 94% for low-, 86% for intermediate-, and 63% for high-risk patients in our cohort. CONCLUSIONS: Primary whole-gland cryoablation is a safe and durable medium-term treatment alternative to radiation therapy and radical prostatectomy for patients with low- and intermediate risk disease. Source of Funding: None © 2022 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 207Issue Supplement 5May 2022Page: e946 Advertisement Copyright & Permissions© 2022 by American Urological Association Education and Research, Inc.MetricsAuthor Information Andrew Wang More articles by this author Greg Mansour More articles by this author Robert Given More articles by this author Expand All Advertisement PDF DownloadLoading ...